To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...

A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

COVID-19 trends also depend on the emergence and spread of new variants. The latest, including NB.1.8.1, are getting better ...

Pfizer-BioNTech's COVID-19 vaccine, which was once hailed as a lifesaver, has been found to have subtle but serious side ...

Dan Peer, a global pioneer in mRNA drug development and director of the Laboratory of Precision NanoMedicine ... Research and Tel Aviv University is an mRNA-based vaccine delivered via lipid ...